Abstract
Platinum-resistant, recurrent, high grade epithelial ovarian carcinoma remains challenging to treat. Chemotherapy produces limited responses with modest survival benefits in the treatment of recurrent disease. In this context, targeted therapies may improve upon conventional therapies. PI3K/AKT pathway alterations are frequently found in several cancer types, including ovarian cancer, and thus AKT inhibition is a rational targeted therapy. Here we report the results of an abbreviated trial of AKT inhibitor MK-2206 in platinum resistant high grade serous ovarian, fallopian tube, and primary peritoneal cancer with PTEN loss.
| Original language | English (US) |
|---|---|
| Article number | 100546 |
| Journal | Gynecologic Oncology Reports |
| Volume | 32 |
| DOIs | |
| State | Published - May 2020 |
| Externally published | Yes |
Keywords
- AKT inhibitor
- MK-2206
- PI3K/AKT pathway
- PTEN
- Platinum resistant ovarian cancer
- Serous ovarian carcinoma
ASJC Scopus subject areas
- Oncology
- Obstetrics and Gynecology
Access to Document
Other files and links
Fingerprint
Dive into the research topics of 'Results of an abbreviated phase II study of AKT inhibitor MK-2206 in the treatment of recurrent platinum-resistant high grade serous ovarian, fallopian tube, or primary peritoneal carcinoma (NCT 01283035)'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Results of an abbreviated phase II study of AKT inhibitor MK-2206 in the treatment of recurrent platinum-resistant high grade serous ovarian, fallopian tube, or primary peritoneal carcinoma (NCT 01283035). / Lee, Elizabeth K.; Tan-Wasielewski, Zhenying; Aghajanian, Carol et al.
In: Gynecologic Oncology Reports, Vol. 32, 100546, 05.2020.Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Results of an abbreviated phase II study of AKT inhibitor MK-2206 in the treatment of recurrent platinum-resistant high grade serous ovarian, fallopian tube, or primary peritoneal carcinoma (NCT 01283035)
AU - Lee, Elizabeth K.
AU - Tan-Wasielewski, Zhenying
AU - Aghajanian, Carol
AU - Coleman, Robert L.
AU - Curtis, Jennifer
AU - Hirsch, Michelle S.
AU - Matulonis, Ursula A.
AU - Cantley, Lewis C.
AU - Mills, Gordon B.
AU - Doyle, L. Austin
AU - Liu, Joyce F.
N1 - Funding Information: GBM is an advisory board member with AstraZeneca, ImmunoMET, Ionis, Nuevolution, PDX bio, Signalchem, Symphogen, and Tarveda, has stock options with Catena Pharmaceuticals, ImmunoMet, SignalChem, Spindle Top Ventures and Tarveda, travel support from Chrysallis Bio, and has licensed technology to Nanostring and Myriad Genetics. GBM is supported by a kind gift from the Miriam and Sheldon Adelson Medical Research Foundation , the Ovarian Cancer Research Foundation , The Breast Cancer Research Foundation , Prospect Creek Foundation , The Komen Foundation SAC110052 , and NCI grants: CA217685 , CA217842 , and CA098258 . Funding Information: LCC owns equity in, receives compensation from, and serves on the scientific advisory board of Agios Pharmaceuticals. He is also a founder of and receives laboratory support from Petra Pharmaceuticals and receives compensation for being on the scientific advisory board of Petra Pharmaceuticals. No drugs from these companies were involved in this study. LCC reports support through the National Cancer Institute of the National Institutes of Health under Award Number R35CA197588 , and through a Stand Up To Cancer Colorectal Cancer Dream Team Translational Research Grant (Grant number: SU2C-AACR-DT22-17 ). Additionally he reports personal fees and other from Cell Signaling Technology and Sanofi USA, grants and personal fees from Pfizer, personal fees from Novo Nordisk, other from Volastra, EIP Pharma, and Faeth, outside the submitted work. In addition, Dr. Cantley has a patent US8883438 licensed to Agios Pharmaceuticals, a patent US8715665 licensed to BIDMC, a patent US5532167 licensed to BIDMC, a patent US8552050 licensed to BIDMC, a patent US6004757 licensed to BIDMC, a patent US9493813 licensed to BIDMC, a patent US9745631 licensed to BIDMC, a patent US9119858 licensed to GENESYS RESEARCH INSTITUTE, a patent US10138479 licensed to BIDMC, a patent US6462173 licensed to CLEAR-COAT HOLDING, a patent US8877791 licensed to BIDMC, a patent US20190010144A1 licensed to Cornell University, California Institute of Biological Research, a patent US20170073760A1 pending to BIDMC, and a patent US20190136238A1 pending to BIDMC. Funding Information: This work was funded by a Stand Up to Cancer Dream Team Translational Research Grant, a Program of the Entertainment Industry Foundation ( SU2C-AACR-DT0209 ). Research grants are administered by the American Association for Cancer Research , the scientific partner of SU2C. The study was sponsored by the National Cancer Institute under the Cancer Therapy Evaluation Program. Funding Information: This work was funded by a Stand Up to Cancer Dream Team Translational Research Grant, a Program of the Entertainment Industry Foundation (SU2C-AACR-DT0209). Research grants are administered by the American Association for Cancer Research, the scientific partner of SU2C. The study was sponsored by the National Cancer Institute under the Cancer Therapy Evaluation Program.GBM is an advisory board member with AstraZeneca, ImmunoMET, Ionis, Nuevolution, PDX bio, Signalchem, Symphogen, and Tarveda, has stock options with Catena Pharmaceuticals, ImmunoMet, SignalChem, Spindle Top Ventures and Tarveda, travel support from Chrysallis Bio, and has licensed technology to Nanostring and Myriad Genetics. GBM is supported by a kind gift from the Miriam and Sheldon Adelson Medical Research Foundation, the Ovarian Cancer Research Foundation, The Breast Cancer Research Foundation, Prospect Creek Foundation, The Komen Foundation SAC110052, and NCI grants: CA217685, CA217842, and CA098258.LCC owns equity in, receives compensation from, and serves on the scientific advisory board of Agios Pharmaceuticals. He is also a founder of and receives laboratory support from Petra Pharmaceuticals and receives compensation for being on the scientific advisory board of Petra Pharmaceuticals. No drugs from these companies were involved in this study. LCC reports support through the National Cancer Institute of the National Institutes of Health under Award Number R35CA197588, and through a Stand Up To Cancer Colorectal Cancer Dream Team Translational Research Grant (Grant number: SU2C-AACR-DT22-17). Additionally he reports personal fees and other from Cell Signaling Technology and Sanofi USA, grants and personal fees from Pfizer, personal fees from Novo Nordisk, other from Volastra, EIP Pharma, and Faeth, outside the submitted work. In addition, Dr. Cantley has a patent US8883438 licensed to Agios Pharmaceuticals, a patent US8715665 licensed to BIDMC, a patent US5532167 licensed to BIDMC, a patent US8552050 licensed to BIDMC, a patent US6004757 licensed to BIDMC, a patent US9493813 licensed to BIDMC, a patent US9745631 licensed to BIDMC, a patent US9119858 licensed to GENESYS RESEARCH INSTITUTE, a patent US10138479 licensed to BIDMC, a patent US6462173 licensed to CLEAR-COAT HOLDING, a patent US8877791 licensed to BIDMC, a patent US20190010144A1 licensed to Cornell University, California Institute of Biological Research, a patent US20170073760A1 pending to BIDMC, and a patent US20190136238A1 pending to BIDMC.CA reports personal fees from Tesaro, Immunogen, Eisai/Merck, and Mateon Therapeutics, grants and personal fees from Clovis, and grants from Genentech, AbbVie, and Astra Zeneca, outside the submitted work. Funding Information: RLC reports grants from the NIH, Gateway Foundation, and V-Foundation during the conduct of this study. He reports grants and personal fees from AstraZeneca, Clovis, Genmab, Roche/Genentech, and Janssen outside of the submitted work. He reports grants from Merck outside the submitted work. He reports personal fees from Tesaro, Medivation, Gamamab, Agenus, Regeneron, and OncoQuest outside the submitted work. Publisher Copyright: © 2020 The Authors
PY - 2020/5
Y1 - 2020/5
N2 - Platinum-resistant, recurrent, high grade epithelial ovarian carcinoma remains challenging to treat. Chemotherapy produces limited responses with modest survival benefits in the treatment of recurrent disease. In this context, targeted therapies may improve upon conventional therapies. PI3K/AKT pathway alterations are frequently found in several cancer types, including ovarian cancer, and thus AKT inhibition is a rational targeted therapy. Here we report the results of an abbreviated trial of AKT inhibitor MK-2206 in platinum resistant high grade serous ovarian, fallopian tube, and primary peritoneal cancer with PTEN loss.
AB - Platinum-resistant, recurrent, high grade epithelial ovarian carcinoma remains challenging to treat. Chemotherapy produces limited responses with modest survival benefits in the treatment of recurrent disease. In this context, targeted therapies may improve upon conventional therapies. PI3K/AKT pathway alterations are frequently found in several cancer types, including ovarian cancer, and thus AKT inhibition is a rational targeted therapy. Here we report the results of an abbreviated trial of AKT inhibitor MK-2206 in platinum resistant high grade serous ovarian, fallopian tube, and primary peritoneal cancer with PTEN loss.
KW - AKT inhibitor
KW - MK-2206
KW - PI3K/AKT pathway
KW - PTEN
KW - Platinum resistant ovarian cancer
KW - Serous ovarian carcinoma
UR - http://www.scopus.com/inward/record.url?scp=85079428988&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85079428988&partnerID=8YFLogxK
U2 - 10.1016/j.gore.2020.100546
DO - 10.1016/j.gore.2020.100546
M3 - Article
AN - SCOPUS:85079428988
VL - 32
JO - Gynecologic Oncology Reports
JF - Gynecologic Oncology Reports
SN - 2211-338X
M1 - 100546
ER -